Advanced Magnetics’ Combidex MRI Agent Will Get Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Imaging agent has a March 30, 2005 user fee date for use in differentiating metastatic and non-metastatic lymph nodes in at-risk cancer patients.
You may also be interested in...
Fate Of AstraZeneca's Iressa To Be Discussed By Advisory Cmte. March 4
FDA will seek input from its Oncologic Drugs Advisory Committee on whether Iressa's accelerated approval should be withdrawn after the non-small cell lung cancer agent failed to show a survival benefit in a confirmatory trial.
Fate Of AstraZeneca's Iressa To Be Discussed By Advisory Cmte. March 4
FDA will seek input from its Oncologic Drugs Advisory Committee on whether Iressa's accelerated approval should be withdrawn after the non-small cell lung cancer agent failed to show a survival benefit in a confirmatory trial.
Advanced Magnetics Combidex “Complete Response”
Advanced Magnetics' Combidex NDA has a user fee goal date of March 30, 2005